SCHEMBL4022371

SCHEMBL4022371

O=C(Nc1ccc(Cl)cc1)c1ccc(Br)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ NPC1 O15118 9/20 0.58
▸ RAB9A P51151 9/20 0.58
▸ ESRRG P62508 2/20 0.58
▸ ESR1 P03372 1/20 0.58
▸ KMT2A Q03164 8/20 0.57
▸ MEN1 O00255 6/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ NFKB1 P19838 3/20 0.57
▸ NFKB2 Q00653 3/20 0.57
▸ RELA Q04206 3/20 0.57
▸ CASP3 P42574 3/20 0.57
▸ SENP7 Q9BQF6 3/20 0.57
▸ POLB P06746 1/20 0.57
▸ SENP8 Q96LD8 1/20 0.57
▸ SENP6 Q9GZR1 1/20 0.57
▸ MAPT P10636 2/20 0.56
▸ TP53 P04637 1/20 0.56
▸ ALOX15 P16050 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24669279 0.86 KMT2A (0.61) NPC1RAB9AESR1KMT2AMEN1
SCHEMBL1199911 0.83 NPC1 (0.63) NPC1RAB9AESRRGESR1KMT2A
SCHEMBL24573395 0.82 NPC1 (0.56) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL31337210 0.81 ESR1 (0.64) LMNAHTTNPC1RAB9AESRRG
SCHEMBL24671088 0.81 MAPT (0.63) LMNAHTTNPC1RAB9AKMT2A
SCHEMBL29803602 0.81 MAPT (0.63) LMNAHTTNPC1RAB9AKMT2A
SCHEMBL9423236 0.78 KMT2A (0.77) LMNAHTTNPC1RAB9AESRRG
SCHEMBL7163662 0.76 RAB9A (0.74) LMNANPC1RAB9AESR1KMT2A
SCHEMBL13191768 0.76 ESRRG (0.55) LMNAHTTNPC1RAB9AESRRG
SCHEMBL4022518 0.75 KMT2A (0.58) HTTNPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025022031-A1 NEW DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2025-01-30 — — WO disclosed
EP-2527326-B1 Novel compounds having 4-pyridylalkylthio group as substituent SANTEN PHARMACEUTICAL CO LTD (JP) 2014-10-08 — — EP disclosed
EP-1602647-B1 NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT SANTEN PHARMACEUTICAL CO LTD (JP) 2013-10-16 — — EP disclosed
EP-1602647-B1 NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT SANTEN PHARMACEUTICAL CO LTD (JP) 2013-10-16 — — EP disclosed
US-8518973-B2 Compounds having 4-pyridylalkylthio group as a substituent SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 — — US disclosed
US-8518973-B2 Compounds having 4-pyridylalkylthio group as a substituent SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 — — US disclosed
US-8518973-B2 Compounds having 4-pyridylalkylthio group as a substituent SANTEN PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 — — US disclosed
US-20120202817-A1 COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 — — US disclosed
US-20120202817-A1 COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 — — US disclosed
US-20120202817-A1 COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 — — US disclosed
US-20060194836-A1 Novel compounds having 4-pyridylalkylthio group as substituent SANTEN PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 — — US disclosed
EP-1602647-A1 NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-12-07 — — EP disclosed
US-20030232841-A1 Heterocyclic carboxamides PFIZER INC 2003-12-18 — — US disclosed
US-6602874-B2 5-(2-(4-methylpiperazin-1-yl)-phenyl)- furan-2-carboxylic acid 4-chlorobenzylamide, for example; treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated PFIZER INC. 2003-08-05 — — US disclosed
US-6537995-B2 Selective serotonin receptor agonists and antagonists used to treat migraines, depression, anxiety and schizophrenia; sertraline PFIZER INC. 2003-03-25 — — US disclosed
EP-0957099-B1 Heterocyclic carboxamides PFIZER PROD INC (US) 2002-11-20 — — EP disclosed
US-20020002168-A1 Heterocyclic carboxamides HOWARD HARRY R (US) 2002-01-03 — — US disclosed
US-20010041705-A1 Heterocyclic carboxamides HOWARD HARRY R (US) 2001-11-15 — — US disclosed
US-6277852-B1 FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS PFIZER INC 2001-08-21 — — US disclosed
EP-0957099-A2 Heterocyclic carboxamides Pfizer Products Inc. (US) 1999-11-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194836-A1 Novel compounds having 4-pyridylalkylthio group as substituent FLT4, FLT1, KDR LMNA 3697/4885HTT 3265/4885NPC1 1632/4885
US-20120202817-A1 COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT FLT1, PYM1, FLT4 LMNA 3964/4885HTT 2754/4885NPC1 1791/4885
US-20020002168-A1 Heterocyclic carboxamides HTR1A, HTR1D, NPY1R LMNA 1300/4885HTT 1234/4885NPC1 2453/4885
US-20030232841-A1 Heterocyclic carboxamides HTR1A, HTR1D, NPY1R LMNA 1300/4885HTT 1234/4885NPC1 2453/4885
US-20010041705-A1 Heterocyclic carboxamides HTR1A, HTR1D, NPY1R LMNA 1300/4885HTT 1234/4885NPC1 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback